Welcome to MyelomaLinks, your monthly source for myeloma news, research updates, clinical trials and Society events. For even more information, regularly visit the Society's Patient Services and Disease Information Web sections.

You are receiving this eNewsletter because you requested it. If you would like to unsubscribe, please follow the links at the bottom of this page.

No Survival Benefit of High Dose Therapy in Multiple Myeloma
High-dose therapy increases the complete remission rate in multiple myeloma patients responsive to chemotherapy, but does not extend progression-free or overall survival, Spanish researchers report.

Aspirin Reduces Thrombosis Risk with Thalidomide-Anthracycline Treatment
Daily low-dose aspirin sharply reduces the risk of thrombotic complications in multiple myeloma patients taking thalidomide along with anthracycline-based chemotherapy, without increasing the likelihood of bleeding complications, according to a new study.

Coping Skills Improve Caregivers' Well Being
A program that has been useful in improving the well-being of caregivers of Alzheimer's disease patients similarly benefits caregivers of cancer patients receiving end-of-life care, new study findings show.

Stem Cell Transplantation: Making an Informed Treatment Choice
Join us for this free telephone education program on Thursday, Feb. 2, 12 p.m. to 1 p.m. ET. The program will feature Armand Keating, M.D., professor and head, Department of Medical Oncology and Hematology Princess Margaret Hospital/Ontario Cancer Institute, Toronto, ON. Participants will have the opportunity to ask questions during the program.

Register online or call (866) 992-9950, ext. 302. Be prepared to include your name, mailing address, telephone number and email address.

This program is sponsored by The Leukemia & Lymphoma Society, in collaboration with the National Marrow Donor Program, and is supported through an educational grant from Amgen.

Exploring Myeloma: An Update on Emerging Therapies 
This free telephone education program took place on Oct. 26. The program featured Asher A. Chanan-Khan, M.D., assistant professor of medicine, Roswell Park Cancer Institute, Buffalo, NY. 

Listen online to the audio archive of this program or download the written transcript.

New Caregivers Program
The Society is pleased to present Lotsa Helping Hands, a free online service that helps manage the everyday tasks of friends, family and co-workers supporting a loved one. Find out more.  

COMMENTARY FROM THE SOCIETY

CLINICAL TRIALS

We invite you to use our Clinical Trial Service, a free and confidential service that can help you find clinical trials that meet your needs. You may also want to visit the National Cancer Institute's Cancer Trials Support Unit, providing resources and information on phase III cancer treatment trials supported by the National Cancer Institute.

Selected Trials

Pazopanib (GW786034) in Subjects with Relapsed or Refractory Multiple Myeloma  More> 

Phase III: Filgrastim with or without AMD3100 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Multiple Myeloma in Remission  More> 

Evaluation of the Role of Epidermal Growth Factor Receptor Inhibition by Cetuximab (Erbitux) in the Management of Previously Treated Multiple Myeloma: A Prospective Phase II Clinical Trial  More>

RESEARCH ROUNDUP

Safety of Prolonged Therapy with Bortezomib in Relapsed or Refractory Multiple Myeloma  More> 

Weekly Cyclophosphamide and Alternate-Day Prednisone: An Effective, Convenient and Well-Tolerated Oral Treatment for Relapsed Multiple Myeloma after Autologous Stem Cell Transplantation  More> 

Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared with Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group  More> 

Targeting Heat Shock Proteins for Immunotherapy in Multiple Myeloma: Generation of Myeloma-Specific CTLs Using Dendritic Cells Pulsed with Tumor-Derived gp96  More>